Dapagliflozin or saxagliptin, which is better for children with type 2 diabetes? Medha Baranwal21 Oct 2023 11:15 AM ISTUSA: A phase III T2NOW trial comparing dapagliflozin or saxagliptin in pediatric type 2 diabetes revealed that Dapagliflozin (Farxiga) lowered HbA1c...
Dapagliflozin safely improves outcomes in people with apparent treatment-resistant hypertension: DELIVER Trial Medha Baranwal16 Oct 2023 11:30 AM ISTUSA: In a post hoc analysis of the DELIVER trial dapagliflozin was shown to be well-tolerated and consistently improved clinical outcomes, including...
Dapagliflozin may improve erectile dysfunction among diabetes patients Medha Baranwal12 Oct 2023 10:45 AM ISTItaly: A recent study published in Diabetic Medicine has shown the positive effect of dapagliflozin on erectile function in patients with type 2...
AstraZeneca Forxiga meets primary endpoint for type 2 diabetes Ruchika Sharma8 Oct 2023 10:00 AM ISTCambridge: AstraZeneca has announced positive results from the T2NOW Phase III trial, one of the largest paediatric type 2 diabetes studies performed...
Linagliptin applicable across wide group of T2DM patients- Latest Indian Position Paper Dr. Nandita Mohan30 Sept 2023 11:30 AM IST As per the latest Indian position statement released in the Journal of the Association of Physicians of India, August 2023 issue, Linagliptin...
USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients MD Brand Connect4 Sept 2023 1:55 PM ISTUSV Pvt. Ltd, a leading drug manufacturer in the diabetes & cardiology segment, has announced the launch of the Liralin Range for the treatment...
SGLT2 inhibitors failed to improve survival in patients hospitalised with COVID-19 Dr. Kamal Kant Kohli31 Aug 2023 10:00 AM ISTUSA: Findings from a recent study failed to support the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients hospitalized with...
ESC 2023 Update: Dapagliflozin fails to improve diuretic efficiency in acute heart failure: DICTATE-AHF trial Dr. Kamal Kant Kohli31 Aug 2023 8:30 AM ISTUSA: Dapagliflozin can be safely started upon hospital admission to rapidly optimise guideline-directed medical therapy (GDMT) among hospitalized...
Sun Pharma Gets CDSCO Panel Nod to Manufacture, Market Antidiabetic FDC Drug Dr. Divya Colin30 Aug 2023 6:00 PM ISTNew Delhi: Pharmaceutical major, Sun Pharma Laboratories has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
AstraZeneca Forxiga approved in China to reduce cardiovascular death, hospitalisation risk in adults with symptomatic chronic heart failure Ruchika Sharma20 Aug 2023 1:30 PM ISTForxiga is a first-in-class, oral, once-daily selective inhibitor of human sodium-glucose co-transporter 2 (SGLT2).
Dapagliflozin suitable adjunct therapy to improve body composition in patients with type 2 diabetes Medha Baranwal17 Aug 2023 11:30 AM ISTSouth Korea: A recent study compared the therapeutic safety and efficacy of dapagliflozin, sitagliptin, or lobeglitazone adjunct therapy in type 2...
USV Launches Jalra Trio for Management of Type 2 Diabetes in India MD Brand Connect11 Aug 2023 12:22 PM ISTUSV Pvt. Ltd, a leading drug manufacturer in the anti-diabetic segment, has announced the launch of the brand Jalra Trio for the treatment of...
